Source: Mergermarket, Novus Capital analysis
Note: Announced deals in the pharmaceutical industry in Russia in 2012-2017
Novus Capital provides a full range of advisory services in M&A transactions: sale and acquisitions of companies/assets, devision of the companies and mergers. Our team engages industry experts and market specialists that helps us evaluating the rationale and deal probability.
Due to our deep industry knowledge and understanding the specifics of the regulatory environment on the Russian pharmaceutical market our team has built long terms relationship with the top management and owners of Russian and multinational companies as well as with other market stakeholders (media, regulatory and public bodies). The combination of all of the above factors help us to be engaged in key M&A transactions on the Russian market.
Novus Capital advises in capital raising transactions for companies willing to finance its development. We help determining the necessary size of the investment capital, optimal split between equity and debt financing, deal structure as well as the list of the most probable investors/lenders.
Novus Capital advises Russian and international pharmaceutical companies in projects for product in-licensing and product out-licensing
Novus Capital acted as a financial advisor to the owners of the Russian company Active Component in a process of selling of a stake to Elbrus Capital (Private Equity Fund). Active component is the leading manufacturer of active pharmaceutical ingredients in Russia.
Novus Capital acted as the financial adviser for the owners of Russian company ALSI Pharma in the sale to the strategic investor Xantis Pharma. ALSI Pharma is a leading company in Russia manufacturing generics. The company specilizes in production of cardiovascular products and drugs for cenral nervous system.
Novus Capital acted as financial advisers for the owners of Dolphin product line, a leading over-the-counter product (medical device) for the treatment of sinusitis (infections of the paranasal sinus) in Russia, in business sale to American company Alvogen
Novus Capital acted as the financial advisor to a leading Russian pharmaceutical communication agency Aaron Lloyd in the creation of the joint venture in Russia with the leading global communications agency Dentsu Aegis Network
Novus Capital partners acted as the financial advisors to the owners of Aqualor brand, the leading over-the-counter product for rinsing the nasal cavity on the Russian market, in selling the product to the strategic investor
Novus Capital partners acted as the financial advisors to Akvion, one of the leading manufacturers of food supplements and pharmaceutical products on the Russian market, in selling the portfolio of five products to the strategic investor
Novus Capital partners acted as the financial advisors to Pharmexpert Group, the leading analytical company for the pharmaceutical industry in Russia, in negotiations, structuring and closing the sale of its business to IMS Health - a leading provider of information, services and technology for the healthcare industry globally
Sergey focuses on mergers and acquisitions and capital raising advisory in Russia. Sergey has been managing numerous M&A engagements in various industries, including pharmaceuticals, FMCG, banking, packaging, metals and mining, oil & gas and others.
Before BIC Securities Sergey worked at KMPG Corporate Finance (Moscow office) for more than 3 years, where he was involved in M&A and fund raising projects.
Sergey graduated from Finance University under the Government of the Russian Federation.
Aleksandr focuses on mergers and acquisitions and capital raising advisory. Aleksandr has been advising and managing M&A transactions in pharmaceuticals, media, industrial packaging, food and beverages.
Before establishing Novus Capital, Aleksandr worked at BIC Securities as a Managing Director and Head of Pharmaceutical and Healthcare practice for more than 5 years. Before BIC Securities, in 2004-2009 Aleksandr was working at Partner position in Prudentia, one of the leading Baltic investment banking firms. During his work in Prudentia Aleksandr specialized in origination and execution of numerous corporate finance advisory engagements and M&A projects. Prior to Prudentia Aleksandr worked in the Corporate Advisory Services Department in Ernst & Young Baltic, as an Economist in the Analytical Department of the Central Bank of Latvia, and also as an Analyst at the Riga Stock Exchange.
Aleksandr holds a B.Sc. degree in Economics from the Stockholm School of Economics in Riga. He has also taken courses in Economics and Business from the Harvard Business School and completed the first level of CFA examination.
Valeriy focuses on mergers and acquisitions (M&A) in healthcare, pharmaceutical and biotechnology industries in Russia
Prior to joining Novus Capital, Valeriy 2.5 years worked in BIC Securities as Senior Associate, where he was responsible for M&A transactions in pharmaceutical industry. Prior to joining BIC Securities, in 2008-2013 Valeriy worked as a Chief Investment Analyst in a healthcare group in Rusnano, Russian state PE/VC Company, where he was responsible for deal structuring, financial modeling, investment documentation preparation and due diligence processes. Valeriy participated in 8 closed deals and made numerous analysis of project applications.
Prior to joining Rusnano, Valeriy worked as an Analyst in Ernst & Young, valuation group, where he was engaged in projects in construction & development, media, energy and business engineering and was responsible for financial modeling, company and industry analysis, and performed business, assets and securities valuation. Before joining Ernst & Young, he worked for two years as an Auditor Assistant in audit department of Deloitte & Touche CIS in telecommunication, media and technology industry, where he performed audit of financial statement under RAS, IFRS & GAAP standards.
Valeriy holds a master degree in Economics, Corporate Finance from National Research University – Higher School of Economics. In addition, he successfully passed levels 1 and 2 of CFA examination.
We believe that one of Novus Capital's success factors is our result orient team
We would be happy to invite to our team goal oriented people with good education and relevant experience, that are willing to reach new professional heights
If you are interested to join Novus Capital please send your CV to firstname.lastname@example.org
The Fund RBV Capital, created with the participation of RVC and R-Pharm, will receive up to 10% of the sale of the Irish Allergan to the American company Bonti. The initial payment will amount to $ 195 million, under certain conditions additional payments may follow.
© All rights reserved, 2015-2018